Cargando…
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
Autophagy and ubiquitin proteasome system are two distinct and cooperative proteolytic pathways. The dual-pathway suppression represents a promising therapeutic strategy for multiple myeloma. Chidamide is a novel benzamide inhibitor of histone deacetylase, and shows potent antimyeloma activity. Here...
Autores principales: | Xu, Li, Feng, Juan, Tang, Hailong, Dong, Ying, Shu, Mimi, Chen, Xiequn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186232/ https://www.ncbi.nlm.nih.gov/pubmed/32341332 http://dx.doi.org/10.1038/s41419-020-2414-3 |
Ejemplares similares
-
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
por: Yang, Yan, et al.
Publicado: (2022) -
The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022) -
Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy
por: Zhang, Yanyu, et al.
Publicado: (2020) -
Bisphosphonates as antimyeloma drugs
por: Modi, N D, et al.
Publicado: (2012) -
The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
por: Zhang, Wanjun, et al.
Publicado: (2020)